» Articles » PMID: 32174803

NBOMes-Highly Potent and Toxic Alternatives of LSD

Overview
Journal Front Neurosci
Date 2020 Mar 17
PMID 32174803
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, a new class of psychedelic compounds named NBOMe (or 25X-NBOMe) has appeared on the illegal drug market. NBOMes are analogs of the 2C family of phenethylamine drugs, originally synthesized by Alexander Shulgin, that contain a -(2-methoxy)benzyl substituent. The most frequently reported drugs from this group are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. NBOMe compounds are ultrapotent and highly efficacious agonists of serotonin 5-HT and 5-HT receptors (Ki values in low nanomolar range) with more than 1000-fold selectivity for 5-HT compared with 5-HT. They display higher affinity for 5-HT receptors than their 2C counterparts and have markedly lower affinity, potency, and efficacy at the 5-HT receptor compared to 5-HT or 5-HT. The drugs are sold as blotter papers, or in powder, liquid, or tablet form, and they are administered sublingually/buccally, intravenously, via nasal insufflations, or by smoking. Since their introduction in the early 2010s, numerous reports have been published on clinical intoxications and fatalities resulting from the consumption of NBOMe compounds. Commonly observed adverse effects include visual and auditory hallucinations, confusion, anxiety, panic and fear, agitation, uncontrollable violent behavior, seizures, excited delirium, and sympathomimetic signs such mydriasis, tachycardia, hypertension, hyperthermia, and diaphoresis. Rhabdomyolysis, disseminated intravascular coagulation, hypoglycemia, metabolic acidosis, and multiorgan failure were also reported. This survey provides an updated overview of the pharmacological properties, pattern of use, metabolism, and desired effects associated with NBOMe use. Special emphasis is given to cases of non-fatal and lethal intoxication involving these compounds. As the analysis of NBOMes in biological materials can be challenging even for laboratories applying modern sensitive techniques, this paper also presents the analytical methods most commonly used for detection and identification of NBOMes and their metabolites.

Citing Articles

Protective Behavioral Strategies for Psychedelic Use: A Mini Review of the Evidence.

Piercey C, Gray B, Sung A, Henry D, Karoly H Psychedelic Med (New Rochelle). 2025; 2(4):234-242.

PMID: 40051484 PMC: 11658379. DOI: 10.1089/psymed.2023.0052.


Toxicodynamic insights of 2C and NBOMe drugs - Is there abuse potential?.

Gil-Martins E, Barbosa D, Borges F, Remiao F, Silva R Toxicol Rep. 2025; 14:101890.

PMID: 39867514 PMC: 11762925. DOI: 10.1016/j.toxrep.2025.101890.


Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics.

Wall M, Harding R, Ertl N, Barba T, Zafar R, Sweeney M Neurosci Insights. 2024; 19:26331055241286518.

PMID: 39386147 PMC: 11462571. DOI: 10.1177/26331055241286518.


The novel psychoactive substance 25E-NBOMe induces reward-related behaviors via dopamine D1 receptor signaling in male rodents.

Kim Y, Kook W, Ma S, Lee B, Ko Y, Kim S Arch Pharm Res. 2024; 47(4):360-376.

PMID: 38551761 DOI: 10.1007/s12272-024-01491-4.


Perioperative considerations for patients exposed to hallucinogens.

Emerick T, Marshall T, Martin T, Ririe D Reg Anesth Pain Med. 2024; 49(12):877-882.

PMID: 38359966 PMC: 11324860. DOI: 10.1136/rapm-2023-104851.


References
1.
Caspar A, Meyer M, Maurer H . Human cytochrome P450 kinetic studies on six N-2-methoxybenzyl (NBOMe)-derived new psychoactive substances using the substrate depletion approach. Toxicol Lett. 2017; 285:1-8. DOI: 10.1016/j.toxlet.2017.12.017. View

2.
Kueppers V, Cooke C . 25I-NBOMe related death in Australia: a case report. Forensic Sci Int. 2015; 249:e15-8. DOI: 10.1016/j.forsciint.2015.02.010. View

3.
Caspar A, Westphal F, Meyer M, Maurer H . LC-high resolution-MS/MS for identification of 69 metabolites of the new psychoactive substance 1-(4-ethylphenyl-)-N-[(2-methoxyphenyl)methyl] propane-2-amine (4-EA-NBOMe) in rat urine and human liver S9 incubates and comparison of its screening.... Anal Bioanal Chem. 2017; 410(3):897-912. DOI: 10.1007/s00216-017-0526-0. View

4.
Lowe L, Peterson B, Couper F . A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State. J Anal Toxicol. 2015; 39(8):668-71. DOI: 10.1093/jat/bkv092. View

5.
Volpi-Abadie J, Kaye A, Kaye A . Serotonin syndrome. Ochsner J. 2013; 13(4):533-40. PMC: 3865832. View